# German Breast Group (GBG)

Source: https://onco.cc/companies/gbg/  
OnCo record `gbg` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The German academic group whose GeparX trials established carboplatin and neoadjuvant strategies in triple-negative breast cancer.

## Summary

The German Breast Group, based in Neu-Isenburg, is the academic group whose Gepar trials established carboplatin and neoadjuvant strategies in triple-negative breast cancer; it was founded in 1997 and is associated with Gunter von Minckwitz and Sibylle Loibl. GeparSixto showed carboplatin raises pathologic complete response rates in TNBC, GeparNuevo tested durvalumab, GeparDouze followed, and its meta-analyses of pathologic complete response as a surrogate endpoint shaped how neoadjuvant trials are designed, with Carsten Denkert also linked. OnCo connects it to carboplatin and durvalumab, to the pCR term, and to partner groups including the NSABP Foundation. Whether pCR reliably predicts long-term benefit for every drug class is the question its own surrogacy work keeps open. Its Gepar series and pCR research programmes are listed in the notes.

## Fields

- Kind: Company
- Last checked: 2026-09-06
- Also known as: German Breast Group; GBG; GBG Forschungs GmbH
- Tags: cooperative-group
- HQ: Neu-Isenburg
- Type: cooperative-group
- Website: https://www.gbg.de

## Notes

- Gepar neoadjuvant trial series
- pCR surrogacy research

## Sources

- Official website: https://www.gbg.de

## Connected records

- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/)
- cancers: [Advanced-stage classical Hodgkin lymphoma (stage III to IV)](https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- terms: [Pathologic complete response (pCR)](https://onco.cc/terms/pcr/)
- people: [Carsten Denkert](https://onco.cc/people/carsten-denkert/), [Gunter von Minckwitz](https://onco.cc/people/gunter-von-minckwitz/), [Sibylle Loibl](https://onco.cc/people/sibylle-loibl/)
- trials: [GeparDouze / NSABP B-59](https://onco.cc/trials/gepardouze/), [GHSG HD21](https://onco.cc/trials/hd21/)
- key papers: [Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials](https://onco.cc/key-papers/paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021/), [Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial](https://onco.cc/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/), [Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto](https://onco.cc/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/), [Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy](https://onco.cc/key-papers/paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- bottlenecks: [Secrecy and intellectual property block collaboration](https://onco.cc/bottlenecks/b-ip-collaboration/)
- institutions: [University Cancer Center Frankfurt (UCT)](https://onco.cc/institutions/uct-frankfurt/)
- companies: [Austrian Breast & Colorectal Cancer Study Group](https://onco.cc/companies/abcsg/), [NSABP Foundation](https://onco.cc/companies/nsabp-foundation/)

---
JSON: https://onco.cc/api/v1/entities/gbg.json